In The Spotlight
DDNews Cancer Research Exclusive
 
 
Recent work with nanoparticles offers a new approach to photo-thermal cancer therapies
 
(Photo credit: University of Toronto)
 
The PEARLs (Photothermal Enhancing Auto-Regulated Liposomes) were developed by Dr. Gang Zheng of the Princess Margaret Cancer Centre and University of Toronto and colleagues, who say they overcome traditional roadblocks to penetrate deeper into tumors.
 
 
NEWS
In their second partnership, the companies will be targeting solid tumors
 
Data from a Phase 1 trial of CPI-613 in combination with high-dose cytarabine and mitoxantrone for relapsed or refractory acute myeloid leukemia (AML) was published in a recent online issue of Clinical Cancer Research
 
Men with testicular cancer more likely to have female relatives with ovarian cancer
 
Combination of immune agonists may fight one of the fastest-moving and deadliest of cancers
 
PGDx to develop companion diagnostic for Five Prime’s bemarituzumab
 
Deal expands Illumina’s oncology offerings for with a CDx version of TruSight Tumor 170 for solid tumors
 
Annual clinical cancer research meeting dives deep into discovery
 
Noncoding mutations found to be a major mechanism in cancer
 
 
FEATURES
(Photo credit: NCI, NIH)
 
 
The latest Annual Report to the Nation shares that cancer survival rates are rising, while incidence and death rates are on a downward trend
 
OPINION
by Dr. Eyal Talor, CEL-SCI
A look at what to expect from the second generation of cancer immunotherapies, after the progress--and pitfalls--of CAR-T cell therapies

by JK Bryan & A Zupnick, Novella
When it comes to oncology clinical trials, drug developers need to stay abreast of the rapidly evolving and competitive landscape while also remaining flexible and innovative in responding to these changes

by Dr. Alexey Eliseev, RXi
The “War on Cancer” declared by the National Cancer Act of 1971 proceeded through a series of evolutionary developments in chemotherapy, radiation treatments and targeted therapies, but until recently was only marginally successful in extending the lives of late-stage cancer patients. A major breakthrough has been achieved over the last decade with the development of immunotherapeutic treatments that empower a patient’s own immune cells to destroy tumors


 
CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2018 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.